Explore

Virginia Tech Professor Receives NSF CAREER Award for Research on Programmable Living Materials

Virginia Tech Professor Receives NSF CAREER Award for Research on Programmable Living Materials

Anna Duraj-Thatte, an assistant professor in the Department of Biological Systems Engineering at Virginia Tech, has been awarded a five-year, $440,000 National Science Foundation (NSF) Faculty Early Career Development Program (CAREER) award. This prestigious award will support her research into creating programmable living materials using bacteria. Her project focuses on utilizing tiny protein fibers produced by bacteria as building blocks for larger materials. By manipulating these proteins, Duraj-Thatte aims to control the mechanical properties of the finished materials, making them stiff, flexible, or somewhere in between. The CAREER award is recognized as the NSF’s most significant award for early-career faculty who demonstrate the potential to lead advancements in both research and education. Duraj-Thatte's work is situated in the emerging field of engineered living materials, which integrates biology, engineering, and materials science to develop materials that can sense, respond, repair, or regenera...

Antimicrobial Peptide-Drug Conjugates Show Promise Against Resistant Bacteria, Face Translational Hurdles

Antimicrobial Peptide-Drug Conjugates Show Promise Against Resistant Bacteria, Face Translational Hurdles

A scientific review published through July 2026 indicates that antimicrobial peptide-drug conjugates (APDCs), which combine peptide and antibiotic functions, have demonstrated significant reductions in minimum inhibitory concentrations against resistant bacteria. These hybrid molecules have, in some cases, restored antibacterial activity against strains resistant to both individual parent compounds, including vancomycin-resistant enterococci. The review examined the rational design of these conjugates, including scaffold selection, antibiotic payloads, and linker chemistries. However, the review also highlighted substantial translational and pharmacological evidence gaps. Pharmacokinetic characterization is largely absent across surveyed programs, and immunomodulatory actions and anti-biofilm mechanisms are only beginning to be explored. In vivo efficacy has been documented for only seven APDC programs, and no dedicated toxicology studies examining systemic safety profiles were identified.

ATP: The Primary Energy Carrier in Living Organisms

ATP: The Primary Energy Carrier in Living Organisms

Adenosine Triphosphate (ATP) is the fundamental energy currency for all living organisms, facilitating various cellular processes. ATP is a phosphorylated macromolecule composed of adenine, ribose, and three phosphate groups. This structure classifies it as a nucleotide, specifically modified for energy storage. The energy within ATP is stored in the chemical bonds between its phosphate groups, which are unstable and possess low activation energy, allowing them to break easily and release substantial energy. Typically, only the terminal phosphate group is removed during cellular reactions, converting ATP into ADP (adenosine diphosphate) through a hydrolysis reaction. This process is catalyzed by the enzyme ATP hydrolase (ATPase), which ensures a timely release of energy to meet cellular demands. The continuous regeneration of ATP from ADP is a reversible reaction, requiring energy input to reattach an inorganic phosphate molecule, a process catalyzed by ATP synthase.

Researchers Develop 'Meat-Tremella' Using Mushroom Scaffolds and Fatty Acids to Advance Cultured Meat Technology

Researchers Develop 'Meat-Tremella' Using Mushroom Scaffolds and Fatty Acids to Advance Cultured Meat Technology

Researchers Develop 'Meat-Tremella' Using Mushroom Scaffolds and Fatty Acids to Advance Cultured Meat Technology

Vizgen Inc. Launches Velocity Lab to Scale Spatial Biology Research for AI-Driven Drug Discovery

Vizgen Inc. Launches Velocity Lab to Scale Spatial Biology Research for AI-Driven Drug Discovery

Vizgen Inc., a leader in spatial multi-omics and developer of MERFISH technology, has announced the launch of Velocity Lab. This new central foundry aims to generate decision-grade spatial biology data at an unprecedented scale, collaborating with partners to advance AI-driven drug discovery. Velocity Lab combines the sensitivity of Vizgen's MERSCOPE Platform with new technologies essential for advanced biological models. Currently, Velocity Lab offers two key capabilities: Volumetric Tissue Mapping, which profiles thick tissue up to 100 µm to capture three-dimensional cell neighborhoods and disease microenvironments, and MERSCOPE CoMap, which enables same-slide RNA and protein co-detection. This combined readout supports studies in target validation, mechanism of action, safety profiling, and treatment response. Vizgen is also preparing Velocity Lab for spatially resolved functional genomics, with early-access collaborations already underway, including a large multinational biopharma partner utilizing Vol...

New Research Links Paraquat Herbicide Inhalation to Parkinson's Disease in Mice, Raising Regulatory Concerns

New Research Links Paraquat Herbicide Inhalation to Parkinson's Disease in Mice, Raising Regulatory Concerns

Preliminary new research from scientists at the University of Rochester and the University of Georgia indicates that exposure to paraquat herbicide through inhalation can cause neurotoxic brain effects consistent with Parkinson's disease. The study, which is a preprint and has not yet undergone peer review, exposed laboratory mice to air containing paraquat particles for 60 days. The results showed reduced dopamine neurons and impaired motor function in the mice. This research is significant because it models human exposure more closely than previous studies, which often involved dietary or injected paraquat. Deborah Cory-Slechta, a neurotoxicologist and co-author, stated that these findings strengthen the existing body of evidence linking paraquat to Parkinson's. The study also noted greater impacts in male mice, mirroring the higher diagnosis rate of Parkinson's in men. This comes as U.S. regulators are reportedly re-examining the chemical, which is banned in approximately 70 other countries, including C...

Gates Foundation and Flagship Pioneering Announce $25 Million Collaboration for Global Health and Agricultural Solutions

Gates Foundation and Flagship Pioneering Announce $25 Million Collaboration for Global Health and Agricultural Solutions

The Gates Foundation and Flagship Pioneering have initiated a five-year collaboration, committing up to $25 million, to discover and advance breakthrough health and agricultural solutions for underserved populations in low- and middle-income countries. This partnership will establish and operate the Pioneering Global Health & Development (PGH&D) Group within Flagship Pioneering, led by Dr. Raj Panjabi. The PGH&D Group aims to identify and initiate a portfolio of programs focusing on global health, women's health, and agriculture. Each program identified will be considered for additional funding from both entities for further development. The collaboration will leverage Flagship Labs' innovation foundry and its ecosystem of over 40 platform companies, combined with the Gates Foundation's expertise in these critical areas, to accelerate the path from scientific discovery to impactful products. The goal is to build access and impact into innovation from its inception, addressing urgent needs in these regions.

EU and India Expand Research Partnership in Horizon Europe Program

EU and India Expand Research Partnership in Horizon Europe Program

The European Union and India have finalized negotiations for India's participation in the €93.5 billion Horizon Europe research and innovation program. This agreement will enable Indian researchers, universities, and businesses to receive direct funding and lead collaborative projects under Horizon Europe’s Pillar II. This pillar specifically supports research in critical areas such as healthcare, digital technologies, industrial innovation, climate, energy, and the bioeconomy. India's involvement is anticipated to commence in January 2027, pending the formal signing of the agreement and necessary approval procedures. This development extends the existing EU–India Agreement for Scientific and Technological Cooperation, which has been prolonged until 2030. Currently, Horizon Europe includes 23 associated non-EU countries, and India's proposed participation is set to bolster international research partnerships and access to scientific expertise, according to the European Commission.

NIST and Department of Energy Collaborate to Repurpose Radioactive Waste for Cancer Treatment

NIST and Department of Energy Collaborate to Repurpose Radioactive Waste for Cancer Treatment

The National Institute of Standards and Technology (NIST) and the Department of Energy (DOE) are collaborating on an initiative to repurpose outdated radioactive materials, previously considered waste, into feedstock for cutting-edge cancer therapies. Manny Mejias, NIST's radiation safety officer, highlighted that research facilities often accumulate outdated radioactive materials, such as radium-226, which were once used in cancer treatment but are no longer medically relevant. Disposing of these materials is costly and poses safety hazards. Through this new program, NIST is providing its legacy radium-226 to the DOE, which will process it into isotopes essential for targeted cancer treatments. This process involves creating custom-made lead cases for safe storage and transport, and rigorous safety protocols are being developed and standardized to allow other institutions to safely transfer their leftover radioactive materials for similar reuse. The goal is to establish a robust domestic supply of these c...

NIH Reorganizes Clinical Trial Funding by Trial Type, Shifting from Disease-Specific NOFOs

NIH Reorganizes Clinical Trial Funding by Trial Type, Shifting from Disease-Specific NOFOs

The National Institutes of Health (NIH) is implementing a significant reorganization of its clinical trial funding process. Historically, individual NIH institutes developed their own Notices of Funding Opportunity (NOFOs) with unique instructions and review criteria for various diseases and research areas. The new approach, announced on November 10, involves creating a suite of five cross-institute NOFOs, each organized by trial type: feasibility, early to definitive, multisite, pragmatic and implementation, and network trials. This means that a feasibility trial, regardless of whether it focuses on heart disease or neurology, will now follow the same NOFO. Institutes will communicate their research priorities through profile pages, strategic plans, and 'Highlighted Topics' instead of relying on disease-specific NOFOs. This change is part of a broader effort by NIH to consolidate funding mechanisms, following similar reclassifications and a reduction in active NOFOs from over 800 in early 2025 to fewer th...

Federal Funding Cuts Impact Young Scientists' Careers and Research at UCLA

Federal Funding Cuts Impact Young Scientists' Careers and Research at UCLA

Federal funding cuts are significantly affecting the careers of young scientists and research initiatives at institutions like UCLA. Elle Rathbun, a neuroscience doctoral student at UCLA, experienced a temporary suspension of her stroke recovery research due to reductions in federal grants. This disruption led her to reconsider a career in academia, even after her funding was eventually restored. The broader impact of these cuts is reshaping the future prospects for young scientists, with many facing uncertainty and challenges in securing long-term research positions. The situation highlights a growing concern within the scientific community regarding the stability and availability of federal support for critical research, particularly for those in the early stages of their careers. The New York Times featured Rathbun's experience as part of a larger report on this issue.

Wharton Generative AI Labs Introduces 'Primer' to Transform Educational Simulations with AI

Wharton Generative AI Labs Introduces 'Primer' to Transform Educational Simulations with AI

Wharton Generative AI Labs has developed 'Primer,' an open-source, LLM-agnostic AI-supported system designed to help educators create adaptive educational simulations. Primer aims to leverage teacher expertise to generate varied and responsive practice scenarios for students, addressing the difficulty and resource intensity of building high-quality simulations traditionally. The system uses a multi-agent approach to execute an educator's instructional intent, allowing AI to improvise dialogue and adapt to students within educator-defined conditions. This 'guided improvisation' shifts the focus from scripting every possible path to designing the learning environment. The project is currently a research prototype, with its prompts, templates, and code available on GitHub for further examination and extension by educators, researchers, and developers.